The National Ataxia Foundation (NAF) announced the hiring of the organization’s first Chief Scientific Officer, Lauren Moore, PhD, following an extensive nationwide search. She will lead NAF’s Ataxia research grant program as well as continue to expand relationships with the growing number of biotech and pharmaceutical companies who are working on developing treatments for Ataxia.
The National Ataxia Foundation (NAF), the Friedreich’s
Ataxia Research Alliance (FARA), and Ataxia UK are pleased to announce the date
for the inaugural International Congress for Ataxia Research (ICAR) to be held at the
Caribe Royale resort in Orlando, Florida, USA on March 15th – 18th, 2022.
The National Ataxia Foundation (NAF) announced today the launch of the NAF Drug Development Collaborative. This pre-competitive pharmaceutical industry consortium has a principal goal of accelerating the development of treatments for Ataxia. The group will address the many shared opportunities and challenges in therapy development for this complex neurological disease.
The National Ataxia Foundation (NAF) Board of Directors and staff announced their new Executive Director, Andrew Rosen, following a nationwide search conducted by a committee of the Board of Directors. He will lead NAF’s efforts in improving the lives of persons affected by Ataxia through support, education, and research.
Non-profit based in Minneapolis will accept resumes from qualified candidates until the position is filled, with submissions to be considered in the first screening due by December 21, 2018.
National Ataxia Foundation celebrates International Ataxia Awareness Day (IAAD) with various outreach strategies to bring awareness to this rare disease.
New preclinical research by Dr. Laura Ranum, a member of NAF’s Medical Research Advisory Board, shows a commonly used Type 2 diabetes drug can improve symptoms in a specific genetic form of ALS and frontotemporal dementia in mice.
Ataxia is a neurological disease that causes balance and motor coordination problems and other symptoms, according to the NAF. There is no cure for Ataxia but the Walk n’ Roll raises money to help research a cure and support those living with the disease.
Have you ever heard of Ataxia? It is a degenerative disease of the nervous system which affects movement in the body.
150,000 people in the U.S. suffer from ataxia. Julie and Ginger speak with WKYC about their story.
“The walk is a walk, obviously, but the roll is because the majority of people who are participating and have ataxia are using either walkers, canes, wheelchairs or scooters. The idea is their caregivers or family members will be walking, and they’ll be rolling.”
Using biochemical and structural studies, they found that in AOA1, aprataxin mutations affect protein stability, how repair proteins bind to DNA, and the rate of the chemical reaction, which is known as catalysis. The team also uncovered a dominant mutation that affects the enzymatic reaction that normally reverses DNA damage.